Melatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, crossover study - PubMed (original) (raw)
Clinical Trial
. 2001 Nov;58(11):1049-52.
doi: 10.1001/archpsyc.58.11.1049.
Affiliations
- PMID: 11695951
- DOI: 10.1001/archpsyc.58.11.1049
Clinical Trial
Melatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, crossover study
E Shamir et al. Arch Gen Psychiatry. 2001 Nov.
Abstract
Background: Antipsychotics remain the mainstay of drug intervention in the management of schizophrenia. However, long-term treatment with antipsychotics is associated with a variety of movement disorders, the most disabling of which is tardive dyskinesia (TD), which occurs in up to 50% of patients hospitalized with chronic schizophrenia. The pathophysiology of TD is still unclear and no definite treatment exists. Both dopamine receptor supersensitivity and oxidative stress-induced neurotoxicity in the nigrostriatal system are apparently implicated. The pineal hormone melatonin is a potent antioxidant and attenuates dopaminergic activity in the striatum and dopamine release from the hypothalamus. Thus, it may have a beneficial effect for both the treatment and prevention of TD.
Methods: Using a double-blind, placebo-controlled, crossover study, we evaluated the efficacy of 10 mg/d of melatonin for 6 weeks in 22 patients with schizophrenia and TD. The primary outcome measure was the change from baseline in Abnormal Involuntary Movement Scale (AIMS) score.
Results: The decrease (mean +/- SD) in AIMS score was 2.45 +/- 1.92 for the melatonin and 0.77 +/- 1.11 for the placebo treatment groups (P<.001). No adverse events or side effects were noted.
Conclusion: This is the first clinical evidence for efficacy of melatonin in the treatment of TD.
Comment in
- Should Sisyphus have taken melatonin?
Glazer WM, Woods SW, Goff D. Glazer WM, et al. Arch Gen Psychiatry. 2001 Nov;58(11):1054-5. doi: 10.1001/archpsyc.58.11.1054. Arch Gen Psychiatry. 2001. PMID: 11695952 No abstract available.
Similar articles
- Is melatonin treatment effective for tardive dyskinesia?
Shamir E, Barak Y, Plopsky I, Zisapel N, Elizur A, Weizman A. Shamir E, et al. J Clin Psychiatry. 2000 Aug;61(8):556-8. doi: 10.4088/jcp.v61n0803. J Clin Psychiatry. 2000. PMID: 10982197 Clinical Trial. - Effectiveness of melatonin in tardive dyskinesia.
Castro F, Carrizo E, Prieto de Rincón D, Rincón CA, Asián T, Medina-Leendertz S, Bonilla E. Castro F, et al. Invest Clin. 2011 Sep;52(3):252-60. Invest Clin. 2011. PMID: 21950196 Clinical Trial. - Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction.
Margolese HC, Chouinard G, Kolivakis TT, Beauclair L, Miller R. Margolese HC, et al. Can J Psychiatry. 2005 Aug;50(9):541-7. doi: 10.1177/070674370505000907. Can J Psychiatry. 2005. PMID: 16262110 Review. - Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia.
McGrath JJ, Soares KV. McGrath JJ, et al. Cochrane Database Syst Rev. 2000;(2):CD000459. doi: 10.1002/14651858.CD000459. Cochrane Database Syst Rev. 2000. PMID: 10796546 Updated. Review.
Cited by
- Efficacy and safety of different pharmacological interventions in the treatment of tardive dyskinesia: a systematic review and network meta-analysis.
Ismail O, Albdour K, Jaber Y, Jaber K, Alsaras A. Ismail O, et al. Eur J Clin Pharmacol. 2024 Oct;80(10):1471-1482. doi: 10.1007/s00228-024-03722-5. Epub 2024 Jul 6. Eur J Clin Pharmacol. 2024. PMID: 38969949 - Therapeutic Potential of Dopamine and Related Drugs as Anti-Inflammatories and Antioxidants in Neuronal and Non-Neuronal Pathologies.
Bandala C, Cárdenas-Rodríguez N, Mendoza-Torreblanca JG, Contreras-García IJ, Martínez-López V, Cruz-Hernández TR, Carro-Rodríguez J, Vargas-Hernández MA, Ignacio-Mejía I, Alfaro-Rodriguez A, Lara-Padilla E. Bandala C, et al. Pharmaceutics. 2023 Feb 18;15(2):693. doi: 10.3390/pharmaceutics15020693. Pharmaceutics. 2023. PMID: 36840015 Free PMC article. Review. - Systematic Review of the Therapeutic Role of Apoptotic Inhibitors in Neurodegeneration and Their Potential Use in Schizophrenia.
Morén C, Treder N, Martínez-Pinteño A, Rodríguez N, Arbelo N, Madero S, Gómez M, Mas S, Gassó P, Parellada E. Morén C, et al. Antioxidants (Basel). 2022 Nov 17;11(11):2275. doi: 10.3390/antiox11112275. Antioxidants (Basel). 2022. PMID: 36421461 Free PMC article. Review. - Pathophysiology, prognosis and treatment of tardive dyskinesia.
Takeuchi H, Mori Y, Tsutsumi Y. Takeuchi H, et al. Ther Adv Psychopharmacol. 2022 Oct 21;12:20451253221117313. doi: 10.1177/20451253221117313. eCollection 2022. Ther Adv Psychopharmacol. 2022. PMID: 36312846 Free PMC article. Review. - Therapeutic use of melatonin in schizophrenia: A systematic review.
Duan C, Jenkins ZM, Castle D. Duan C, et al. World J Psychiatry. 2021 Aug 19;11(8):463-476. doi: 10.5498/wjp.v11.i8.463. eCollection 2021 Aug 19. World J Psychiatry. 2021. PMID: 34513608 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical